Go look at my other posts. I am using a UK government site not a company projections. Big difference. And yes there are hard limits go Google it like you did this article.
Thr point is the UK isn't the market where you are going to get reimbursement and subsequent real profitability. It is a nice secondary market. US,Japan, EU are where you should hit first if profit is truly a motivation.
Dilution for the unforeseeable future is the bottomline
The GBM treatment field a now full of players with plenty of trials that'll cut into L's hypothetical UK business model. mRNA will almost certainly take center seat.